ScreenerHero

PHIL Philogen S.p.A.

BIT · IT · Healthcare · Biotechnology · philogen.com
22.25EUR0.00%Mkt Cap: 972.98M $P/E: 3.99

Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company deve…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap972.98M USD
Enterprise Value619.37M USD
Revenue (TTM)342.68M USD
Gross Profit335.89M USD
Net Income (TTM)249.65M USD
Revenue/Share7.81 EUR
Last Price22.25 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees230
CountryIT
SectorHealthcare
IndustryBiotechnology
ISINIT0005373789
Valuation
P/E (Trailing)3.99
P/E (Forward)-89.25
PEG—
EV/EBITDA2.25
EV/Revenue1.81
P/S2.84
P/B2.70
EPS (TTM)5.58
EPS (Forward)-0.25
52W Range
19.5642% of range26.00
52W High26.00 EUR
52W Low19.56 EUR
Profitability
Gross Margin98.31%
Oper. Margin-578.82%
EBITDA Margin80.19%
Profit Margin73.07%
ROE61.43%
ROA52.52%
Growth
Revenue Growth-52.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF291.27M USD
CapEx (TTM)3.95M USD
FCF Margin62.06%
FCF Yield21.86%
Net Debt-354.02M USD
Net Debt/EBITDA-1.29
Balance Sheet
Debt/Equity0.03
Current Ratio6.99
Quick Ratio6.92
Book Value/Sh8.24 EUR
Cash/Share8.38 EUR
Dividends
Fwd Div Rate0.70 EUR
Trail. Div Rate0.70 EUR
Div. Yield3.17%
5Y Avg Yield—
Payout Ratio12.54%
Ex-Div DateMay 18, 2026
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.33 EUR
Upside (mean)+27.3%
Target Range21.00 EUR – 34.00 EUR
21.00+27.3% to mean34.00
# Analysts3
Ownership
Shares Out.28.86M
Float10.71M
Insiders62.15%
Institutions9.21%
Technical
SMA 5023.29 (-4.5%)
SMA 20022.55 (-1.3%)
Beta-0.03
S&P 52W Chg16.45%
Avg Vol (30d)18.33K
Avg Vol (10d)20.03K
Technical Indicators
RSI (14)40.6
MACD-0.3222
MACD Signal-0.2645
MACD Hist.-0.0577
BB Upper23.97 EUR
BB Middle22.82 EUR
BB Lower21.66 EUR
BB Width10.15%
ATR (14)0.6084 EUR
Vol Ratio (20d)1.35x